Noreen Shaaban
Endocrinology, Diabetes & Metabolism · Doral, FLNPI 1760090740
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 418 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,570 and has fallen 78.8% since, to $755 in 2025.
Across 418 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Amgen$774
- Boehringer Ingelheim$727
- Novo Nordisk$687
- Mannkind Corporation$653
- AstraZeneca$554
- plus $5K from 28 others
Across 285 payments — averaging $468.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$83K
- Vertex$51K
What the payments were for
- Food & beverage$9,520100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 60 | $1,144 |
| Amgen(2 entities) | 24 | $774 |
| Boehringer Ingelheim | 31 | $727 |
| Novo Nordisk | 30 | $687 |
| Mannkind Corporation | 29 | $653 |
| AstraZeneca(2 entities) | 15 | $554 |
| Novartis | 28 | $502 |
| Sanofi-aventis U.S. LLC | 27 | $461 |
| AbbVie | 24 | $439 |
| Dexcom, Inc. | 14 | $426 |
| Xeris Pharmaceuticals, Inc. | 22 | $391 |
| Bayer | 17 | $365 |
| Corcept Therapeutics | 14 | $360 |
| Kyowa Kirin, Inc. | 7 | $322 |
| Tandem Diabetes Care, Inc. | 10 | $284 |
| Radius Health, Inc. | 15 | $281 |
| Esperion Therapeutics, Inc. | 4 | $173 |
| Lifescan, Inc. | 9 | $155 |
| Pfizer | 7 | $134 |
| Cequr Corporation | 1 | $132 |
| Recordati_rare_diseases_inc. | 6 | $120 |
| Halozyme Inc | 5 | $101 |
| Ascendis Pharma Endocrinology Inc | 3 | $65 |
| Antares Pharma, Inc. | 3 | $54 |
| Amphastar Pharmaceuticals, Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $45 |
| IBSA Pharma Inc. | 2 | $33 |
| Insulet Corporation | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $19 |
| Cardinal Health 414 LLC | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Roche Diabetes Care, Inc. | 1 | $16 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,563 in reported general payments places this provider in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 24 | $636 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Doral
- Brenda Acosta AshbyDoral$117K
- Krista GonzalesDoral$85K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.